A new treatment against Clostridium difficile

A new treatment against Clostridium difficile Clostridium difficile associated diarrheas (ODD) are one of the major secondary infections encountered in patients under antibiotics therapy. In spite of inherent drawbacks associated with vancomycin and metronidazole, these two broad-spectrum antibiotics are currently prescribed for the treatment of ODD. The natural molecule known as tiacumicin B or fidaxomicin has recently been approved by FDA to treat Clostridium difficile infections. This article briefly recalls the essential of antibiotics, of Clostridium difficile and discusses the isolation, biosynthesis, mode of action and structure-activity relationship of tiacumicin B.